MDGL - Madrigal Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
West Conshohocken,
United States
Type: Equity
MDGL price evolution
MDGL
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $499.6 | $622.52 | $99.92 | |
| Short term investments | $563.2 | $436.55 | $534.22 | |
| Net receivables | $6.9 | |||
| Inventory | $7.07 | $0.85 | ||
| Total current assets | $1091.73 | $1073.95 | $637.28 | |
| Long term investments | ||||
| Property, plant & equipment | $3.15 | $3.33 | $3.27 | |
| Goodwill & intangible assets | $4.91 | $5 | ||
| Total noncurrent assets | $8.06 | $8.33 | $3.27 | |
| Total investments | $563.2 | $436.55 | $534.22 | |
| Total assets | $1099.79 | $1082.28 | $640.55 | |
| Current liabilities | ||||
| Accounts payable | $8.99 | $21.53 | $28.04 | |
| Deferred revenue | ||||
| Short long term debt | $0.56 | $0.54 | $0.53 | |
| Total current liabilities | $125.16 | $114.34 | $118.55 | |
| Long term debt | $117.51 | $117.18 | $116.67 | |
| Total noncurrent liabilities | $117.51 | $117.18 | $116.67 | |
| Total debt | $118.06 | $117.72 | $117.19 | |
| Total liabilities | $242.67 | $231.52 | $235.21 | |
| Shareholders' equity | ||||
| Retained earnings | -$1635.8 | -$1483.83 | -$1336.29 | |
| Other shareholder equity | -$0.37 | -$0.17 | $0.47 | |
| Total shareholder equity | $857.12 | $850.76 | $405.33 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.92 | $331.55 | $36.27 | $54 |
| Short term investments | $534.22 | $27.23 | $234.08 | $230.15 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $637.28 | $361.37 | $271.68 | $285.16 |
| Long term investments | ||||
| Property, plant & equipment | $3.27 | $1.2 | $1.65 | $1.83 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.27 | $1.2 | $1.65 | $1.83 |
| Total investments | $534.22 | $27.23 | $234.08 | $230.15 |
| Total assets | $640.55 | $362.57 | $273.33 | $287 |
| Current liabilities | ||||
| Accounts payable | $28.04 | $23.83 | $21.38 | $1.02 |
| Deferred revenue | ||||
| Short long term debt | $0.53 | $0.6 | $0.41 | $0.32 |
| Total current liabilities | $118.55 | $115.89 | $76.84 | $46.56 |
| Long term debt | $116.67 | $49.29 | $0.39 | $0.47 |
| Total noncurrent liabilities | $116.67 | $49.29 | $0.39 | $0.47 |
| Total debt | $117.19 | $49.89 | $0.8 | $0.79 |
| Total liabilities | $235.21 | $165.18 | $77.22 | $47.02 |
| Shareholders' equity | ||||
| Retained earnings | -$1336.29 | -$962.66 | -$667.31 | -$425.46 |
| Other shareholder equity | $0.47 | -$0.03 | -$0.08 | $0.05 |
| Total shareholder equity | $405.33 | $197.39 | $196.11 | $239.97 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $62.17 | $14.64 | ||
| Cost of revenue | $0.64 | |||
| Gross Profit | $60.02 | $14 | ||
| Operating activities | ||||
| Research & development | $71.09 | $71.24 | $70.64 | |
| Selling, general & administrative | $105.45 | $80.8 | $46.54 | |
| Total operating expenses | $176.33 | $176.54 | $152.04 | $117.18 |
| Operating income | -$162.54 | -$152.04 | -$117.18 | |
| Income from continuing operations | ||||
| EBIT | -$148.31 | -$143.7 | -$108.22 | |
| Income tax expense | ||||
| Interest expense | $9.34 | $3.66 | $3.84 | $3.97 |
| Net income | ||||
| Net income | -$106.96 | -$151.97 | -$147.54 | -$112.19 |
| Income (for common shares) | -$151.97 | -$147.54 | -$112.19 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $272.35 | $245.44 | $205.16 | $184.81 |
| Selling, general & administrative | $108.15 | $48.13 | $37.32 | $21.86 |
| Total operating expenses | $380.5 | $293.57 | $242.48 | $206.67 |
| Operating income | -$380.5 | -$293.57 | -$242.48 | -$206.67 |
| Income from continuing operations | ||||
| EBIT | -$360.92 | -$291.39 | -$241.85 | -$202.24 |
| Income tax expense | ||||
| Interest expense | $12.71 | $3.96 | ||
| Net income | ||||
| Net income | -$373.63 | -$295.35 | -$241.85 | -$202.24 |
| Income (for common shares) | -$373.63 | -$295.35 | -$241.85 | -$202.24 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$151.97 | -$147.54 | -$112.19 | |
| Operating activities | ||||
| Depreciation | $0.27 | $0.17 | $0.14 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $24.4 | $19.9 | $14.85 | |
| Total cash flows from operations | -$134.94 | -$149.16 | -$79.93 | |
| Investing activities | ||||
| Capital expenditures | -$5.13 | -$0.36 | -$1.04 | |
| Investments | -$116.97 | $98.41 | -$361.09 | |
| Total cash flows from investing | -$226.44 | -$122.1 | $98.05 | -$362.12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $134.12 | $573.71 | $479.92 | |
| Net borrowings | ||||
| Total cash flows from financing | $715.29 | $134.12 | $573.71 | $479.92 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $137.77 | -$122.92 | $522.6 | $37.86 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$373.63 | -$295.35 | -$241.85 | -$202.24 |
| Operating activities | ||||
| Depreciation | $0.53 | $0.47 | $0.41 | $0.47 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $49.73 | $31.63 | $26.87 | $20.73 |
| Total cash flows from operations | -$324.23 | -$224.86 | -$183.92 | -$157.56 |
| Investing activities | ||||
| Capital expenditures | -$1.48 | -$0.22 | -$0.21 | -$0.33 |
| Investments | -$501.04 | $206.9 | -$4.85 | $160.11 |
| Total cash flows from investing | -$502.52 | $206.69 | -$5.05 | $159.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $530.48 | $264.34 | $171.24 | $5.09 |
| Net borrowings | $64.64 | $49.11 | ||
| Total cash flows from financing | $595.12 | $313.45 | $171.24 | $5.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$231.63 | $295.28 | -$17.73 | $7.31 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $76.81M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$518.67M |
| Revenue Q/Q | InfinityT% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.58 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |